US NIH Resumes Indian Trials But Keen On 'Elaborations' Of Rules
This article was originally published in SRA
More than two years after it cut back on Indian clinical trials, the US National Institutes of Health, the largest public funder of biomedical research in the world, appears to have recommenced activity in the area, albeit on a cautious note.
You may also be interested in...
India has tweaked another set of trial rules including one that capped the number of trials per investigator as it seeks to clear the logjam of regulatory requirements that has been stifling the clinical research segment in the country. Much though could depend on actual implementation and it remains to be seen if such measures can alter the course of sector.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.